Biomarker signature and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome

Autor: Camilla C.S. van der Hoef, Eva M. Boorsma, Johanna E. Emmens, Bart J. van Essen, Marco Metra, Leong L. Ng, Stefan D. Anker, Kenneth Dickstein, Ify R. Mordi, Adel Dihoum, Chim C. Lang, Dirk J. van Veldhuisen, Carolyn S.P. Lam, Adriaan A. Voors

Publikováno v: European Journal of Heart Failure. 25:163-173

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393a3d8dc20b769a29d160d02095859e
https://doi.org/10.1002/ejhf.2760

Albuminuria as a marker of systemic congestion in patients with heart failure

Autor: Eva M Boorsma, Jozine M ter Maaten, Kevin Damman, Bart J van Essen, Faiez Zannad, Dirk J van Veldhuisen, Nilesh J Samani, Kenneth Dickstein, Marco Metra, Gerasimos Filippatos, Chim C Lang, Leong Ng, Stefan D Anker, John G Cleland, Pierpaolo Pellicori, Ron T Gansevoort, Hiddo J L Heerspink, Adriaan A Voors, Johanna E Emmens

Publikováno v: European Heart Journal
European Heart Journal, 2023, 44 (5), pp.368-380. ⟨10.1093/eurheartj/ehac528⟩
European Heart Journal, 44(5):ehac528, 368-380. Oxford University Press

Aims Albuminuria is common in patients with heart failure and associated with worse outcomes. The underlying pathophysiological mechanism of albuminuria in heart failure is still incompletely understood. The association of clinical characteristics an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60f2fed201c592006289a8183d5a402
https://hal.univ-lorraine.fr/hal-03798590/document

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure

Autor: Adriaan A. Voors, Eva M Boorsma, Kevin Damman, Jasper Tromp, Hiddo J.L. Heerspink, Peter van der Meer, Joost C. Beusekamp

Publikováno v: European Journal of Heart Failure, 23(6). Wiley
European Journal of Heart Failure

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cae2c3f8a66a89187c1de1f6bdb3e756
https://doi.org/10.1002/ejhf.2197

Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)

Autor: Henk P. Swart, Adriaan A. Voors, Eva M Boorsma, Kevin Damman, Hiddo J.L. Heerspink, Tom D. J. Smilde, Arif Elvan, Joost C. Beusekamp, J W Martijn van Eck

Publikováno v: European Journal of Heart Failure, 22(4), 713-722. Wiley

Aims: Inhibition of sodium–glucose co-transporter 2 (SGLT2) reduces the risk of death and heart failure (HF) admissions in patients with chronic HF. However, safety and clinical efficacy of SGLT2 inhibitors in patients with acute decompensated HF a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ca63c042c1308a1004cc32674720f39
https://doi.org/10.1002/ejhf.1713

Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure

Autor: Stefan D. Anker, Chim C. Lang, Marco Metra, Jozine M. ter Maaten, Eva M Boorsma, Adriaan A. Voors, Kevin Damman, Karine Santos, Dirk J. van Veldhuisen, Gerasimos Filippatos, Kenneth Dickstein

Publikováno v: European Journal of Heart Failure
European Journal of Heart Failure, 23(6), 947-953. Wiley

Aims Recently, dipeptidyl peptidase 3 (DPP3) has been discovered as the peptidase responsible for cleavage of angiotensin (1–7) [Ang (1–7)]. Ang (1–7) is part of the angiotensin‐converting enzyme–Ang (1–7)–Mas pathway which is considere

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffb4c11f0407a29b6fa71715680d0ece
https://pubmed.ncbi.nlm.nih.gov/33742751